Health-care companies rose amid drug development.
Ultragenyx shares rallied after the Food and Drug Administration granted commercial approval to one of its gene therapies for treating a rare pediatric neurodevelopmental disorder.
Shares of Tempus AI, a firm that uses artificial intelligence for medical screening, rallied after estimates of its likely Medicare reimbursement rates for cancer products.
States haven't yet been able to obtain Covid-19 shots from the Centers for Disease Control and Prevention, delaying their distribution to millions of children through federal programs.